LY 541850 

LY 541850 is claimed from human ionotropic and metabotropic glutamate (mGlu) receptors expressed in non-neuronal cells. LY541850 is a selective orthosteric mGlu2 agonist and mGlu3 antagonist with IC₅₀ values of 0.161 μM and 0.038 μM, respectively^[1].

LY 541850 (intraperitoneal injection; 10 mg/kg-300 mg/kg; 15 min prior) induces a concentration-dependent inhibition of the TAP evoked fEPSPs in CA1-SLM in 10-16 week old (EC₅₀ 42 nM) in CD-1 mice^[1].
LY 541850 (intraperitoneal injection; 10 mg/kg-300 mg/kg; 30 min prior) reduces the increased locomotor activity of phencyclidine and amphetamine in a dose-dependent manner in male ICR mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

199.20

C₉H₁₃NO₄

852679-76-6

O=C([C@@]1(N)[C@]2([H])[C@@H](C(O)=O)[C@]2([H])[C@H](C)C1)O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Hanna L, et al. Differentiating the roles of mGlu2 and mGlu3 receptors using LY541850, an mGlu2 agonist/mGlu3 antagonist. Neuropharmacology. 2013 Mar;66:114-21.  [Content Brief]